Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Srinivas Nalamachu

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Pain Management|March 17, 2016
Evolution to low-dose NSAID therapyJoseph V Pergolizzi, Robert B Raffa, Srinivas Nalamachu, et al.
Journal of Opioid Management|May 28, 2013
Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic painSrinivas Nalamachu, Donna Ruck, Rahul Nalamasu, et al.
Journal of Pain Research|May 1, 2013
Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?Kai-Uwe Kern, Srinivas Nalamachu, Louis Brasseur, et al.
Medgenmed : Medscape General Medicine|April 5, 2007
A comparison of the lidocaine patch 5% vs naproxen 500 mg twice daily for the relief of pain associated with carpal tunnel syndrome: a 6-week, randomized, parallel-group studySrinivas Nalamachu, R S Crockett, Arnold R Gammaitoni, et al.
Pain Practice : the Official Journal of World Institute of Pain|August 23, 2015
Safety and Tolerability of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets: Analysis of 11 Clinical TrialsThomas Barrett, Kenneth Kostenbader, Srinivas Nalamachu, et al.
Current Medical Research and Opinion|March 31, 2016
Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodoneSrinivas Nalamachu, Ernest A Kopecky, Robert Taylor, et al.
Sleep Disorders|March 21, 2014
Fast-Acting Sublingual Zolpidem for Middle-of-the-Night WakefulnessJoseph V Pergolizzi, Robert Taylor, Robert B Raffa, et al.
Journal of Opioid Management|July 26, 2018
Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid useSrinivas Nalamachu, Jeffrey Gudin, Catherine Datto, et al.
Current Pharmaceutical Design|March 20, 2014
Pain and obesity in the older adultRobert Taylor, Joseph V Pergolizzi, Robert B Raffa, et al.
Current Medical Research and Opinion|January 7, 2011
Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer painSrinivas Nalamachu, David Hassman, Mark S Wallace, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Pain Management|March 17, 2016
Evolution to low-dose NSAID therapyJoseph V Pergolizzi, Robert B Raffa, Srinivas Nalamachu, et al.
Journal of Opioid Management|May 28, 2013
Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic painSrinivas Nalamachu, Donna Ruck, Rahul Nalamasu, et al.
Journal of Pain Research|May 1, 2013
Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain?Kai-Uwe Kern, Srinivas Nalamachu, Louis Brasseur, et al.
Medgenmed : Medscape General Medicine|April 5, 2007
A comparison of the lidocaine patch 5% vs naproxen 500 mg twice daily for the relief of pain associated with carpal tunnel syndrome: a 6-week, randomized, parallel-group studySrinivas Nalamachu, R S Crockett, Arnold R Gammaitoni, et al.
Pain Practice : the Official Journal of World Institute of Pain|August 23, 2015
Safety and Tolerability of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets: Analysis of 11 Clinical TrialsThomas Barrett, Kenneth Kostenbader, Srinivas Nalamachu, et al.
Current Medical Research and Opinion|March 31, 2016
Evaluation of the durability of pain relief throughout a 12 hour dosing interval of a novel, extended-release, abuse-deterrent formulation of oxycodoneSrinivas Nalamachu, Ernest A Kopecky, Robert Taylor, et al.
Sleep Disorders|March 21, 2014
Fast-Acting Sublingual Zolpidem for Middle-of-the-Night WakefulnessJoseph V Pergolizzi, Robert Taylor, Robert B Raffa, et al.
Journal of Opioid Management|July 26, 2018
Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid useSrinivas Nalamachu, Jeffrey Gudin, Catherine Datto, et al.
Current Pharmaceutical Design|March 20, 2014
Pain and obesity in the older adultRobert Taylor, Joseph V Pergolizzi, Robert B Raffa, et al.
Current Medical Research and Opinion|January 7, 2011
Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer painSrinivas Nalamachu, David Hassman, Mark S Wallace, et al.
Pageof 6